HCP 1101

Drug Profile

HCP 1101

Alternative Names: HCP-1101

Latest Information Update: 10 Oct 2015

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Small molecules
  • Mechanism of Action Reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 10 Oct 2015 Discontinued - Phase-III for Benign prostatic hyperplasia in South Korea (unspecified route)
  • 19 Mar 2015 Phase-III clinical trials in Benign prostatic hyperplasia in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top